Hematology Division, Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Stem Cell Rev Rep. 2011 Jun;7(2):425-33. doi: 10.1007/s12015-010-9183-9.
Cord blood (CB) is an important alternative source of hematopoietic stem cells (HSCs) for transplantation today. The principal drawbacks of cord blood transplantation are the limited number of hematopoietic stem cells and a long time to engraftment. Several promising approaches for engraftment enhancement are under intensive investigation. Such are transplantation with two cord blood units, co transplantation of cord blood and haploidentical HSCs and different methods for expansion of cord blood hematopoietic stem cells. In addition there are several ways for improving of homing of HSCs such as co- infusion of CB hematopoietic stem cells and mesenchymal stem cells, administration of parathyroid hormone (PTH), intra- bone transplantation and targeting the CXCR4/SDF1 system. These strategies are expected to increase the availability of transplantation to adults, for whom the chance to find a cord blood suitable for a single unit transplant is small. Recent advances in elucidation of the molecular mechanisms responsible for the proliferation and self-renewal of hematopoietic stem cells may bring further improvement of the outcomes of cord blood transplantation. This review summarizes the recent progress in the field of cord blood derived hematopoietic stem cells. It presents the strategies applied and points out directions for the future.
脐带血(CB)是当今移植造血干细胞(HSCs)的重要替代来源。脐带血移植的主要缺点是造血干细胞数量有限,植入时间长。目前正在深入研究几种有前途的植入增强方法。例如,使用两个脐带血单位进行移植,将脐带血和半相合 HSCs 共移植,以及不同的方法来扩增脐带血造血干细胞。此外,还有几种方法可以改善 HSCs 的归巢,例如共输注 CB 造血干细胞和间充质干细胞、施用甲状旁腺激素(PTH)、骨内移植和靶向 CXCR4/SDF1 系统。这些策略有望增加成人移植的机会,因为对于成年人来说,找到适合单个单位移植的脐带血的机会很小。阐明造血干细胞增殖和自我更新的分子机制的最新进展可能会进一步改善脐带血移植的结果。这篇综述总结了脐带血衍生造血干细胞领域的最新进展。它介绍了所应用的策略,并指出了未来的方向。